The customer-producer relationship within the pharmaceutical supply chain is becoming so abstract that the producer is losing sight of the simple realities that underpin the business model, according to a new industry report from global supply chain consultancy Crimson & Co. The report highlights an alarming trend whereby those at the sharp end, particularly the people who are developing, making, selling or moving are continually becoming marginalised, abstracting them further and further from the customer. Program management and complex organisational structures continue to consume excessive amounts of management time.
In order to address this, Kerry Pickstone, Head of Life Sciences at Crimson & Co., says those within the pharmaceutical supply chain should actively be looking to reverse this trend and reengage with the customer.
“Over the next five years, excellent pharmaceutical supply chains will be those who stand up and stop the trend. They will focus on getting closer to the customer and their own colleagues, doing the fundamentals right, while taking an end-to-end view of the supply chain,” said Pickstone.
The report aims to highlight not only the critical challenges to reducing abstractions in the pharmaceutical supply chain, but also the changes which need to be made in order to reengage the customer-producer relationship. This includes:
Pickstone concluded, “Firms should be looking to implement a simpler, more coherent and profitable way forward, even if it reduces the overall economies of scale that appear available from centralisation, integration and coordination. Ultimately, it’s time to go back and put the customer again at the heart of the business.”